New insulin algorithm aims to simplify diabetes management
NCT ID NCT07593625
First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 3 times
Summary
This study tests a next-generation automated insulin delivery system (Omnipod M) in up to 40 adults with type 1 diabetes. The goal is to see if the system safely improves blood sugar control by reducing dangerously low and high levels. Participants will use the device during hotel and outpatient periods, and researchers will compare glucose readings to their usual care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES (DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Otago
RECRUITINGChristchurch, 8140, New Zealand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could your bone health decide if a dental implant lasts?
- Can an app and cash rewards tame type 1 diabetes in young adults?
- Ancient wisdom meets modern care: could chinese medicine boost diabetes Self-Management?
- Smart insulin pump aims to end dangerous nighttime blood sugar swings
- Could diabetes be silently damaging your hearing?
- Hidden liver risk in type 1 diabetes: a new study investigates